gemfibrozil has been researched along with Cancer of Liver in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganji, SH; Kamanna, VS; Kashyap, ML; Zhu, D | 1 |
| Cattley, RC | 1 |
| Illingworth, R | 1 |
| Chuang, MY; Jin, FY; Kamanna, VS; Kashyap, ML; Morgan, K | 1 |
| Abe, K; Goto, D; Kuwano, M; Okimoto, T; Ono, M; Shimotsu, H; Tsujita, Y | 1 |
| Chen, ZQ; Deeley, RG; Honjo, T; Khalili, K; Mohan, WS; Tam, SP; Zhang, X | 1 |
| Baugé, E; Chinetti, G; Clavey, V; Copin, C; Dallongeville, J; Fruchart, J; Fruchart, JC; Mariotte, MC; Staels, B | 1 |
7 other study(ies) available for gemfibrozil and Cancer of Liver
| Article | Year |
|---|---|
Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells.
Topics: Acyltransferases; Apolipoproteins B; Diacylglycerol O-Acyltransferase; Gemfibrozil; Hepatoblastoma; Humans; Liver; Liver Neoplasms; Microsomes; Sensitivity and Specificity; Triglycerides; Tumor Cells, Cultured | 2002 |
Carcinogenicity of lipid-lowering drugs.
Topics: Acyl-CoA Oxidase; Animals; Gemfibrozil; Humans; Hypolipidemic Agents; Liver; Liver Neoplasms; Microbodies; Oxidoreductases; Receptors, Cytoplasmic and Nuclear; Rodentia; Transcription Factors | 1996 |
Carcinogenicity of lipid-lowering drugs.
Topics: Acyl Coenzyme A; Gemfibrozil; Humans; Hypolipidemic Agents; Liver; Liver Neoplasms; Lovastatin | 1996 |
Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2).
Topics: Apolipoprotein A-I; Carcinoma, Hepatocellular; Cholesterol; Gemfibrozil; Gene Expression Regulation, Neoplastic; Half-Life; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Liver Neoplasms; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; Stimulation, Chemical; Transcription, Genetic; Tumor Cells, Cultured | 1996 |
Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts.
Topics: Carcinoma, Hepatocellular; Dactinomycin; ErbB Receptors; Gemfibrozil; Gene Expression Regulation, Neoplastic; Genes, Reporter; Half-Life; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Neoplasms; Mevalonic Acid; Neoplasm Proteins; Pravastatin; Promoter Regions, Genetic; Receptors, LDL; RNA, Messenger; RNA, Neoplasm; Transfection; Tumor Cells, Cultured; Up-Regulation | 1997 |
Human S mu binding protein-2 binds to the drug response element and transactivates the human apoA-I promoter: role of gemfibrozil.
Topics: Apolipoprotein A-I; Blotting, Northern; Carcinoma, Hepatocellular; DNA-Binding Proteins; Gemfibrozil; Gene Expression; Humans; Hypolipidemic Agents; Liver Neoplasms; Promoter Regions, Genetic; RNA, Messenger; Trans-Activators; Transcription Factors; Transfection; Tumor Cells, Cultured | 1998 |
Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Blood; Carcinoma, Hepatocellular; Cattle; Culture Media; DNA-Binding Proteins; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Liver Neoplasms; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 1999 |